Next-Generation ALK Inhibitors for NSCLC

preview_player
Показать описание
Gregory J. Riely, MD, and Alice T. Shaw, MD, PhD, discuss the next-generation ALK inhibitors: alectinib, brigatinib, and lorlatinib.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Next-Generation ALK Inhibitors 0:06:41

Next-Generation ALK Inhibitors for NSCLC

Next Generation ALK 0:08:35

Next Generation ALK Inhibitors for NSCLC

Efficacy of Next-Generation 0:04:23

Efficacy of Next-Generation ALK Inhibitors in NSCLC

Dr. Rotow on 0:01:02

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

Utilizing Next-Generation ALK 0:05:18

Utilizing Next-Generation ALK Inhibitors in NSCLC

Next-generation ALK inhibitors: 0:01:42

Next-generation ALK inhibitors: treatment sequencing and resistance

Upfront Use of 0:06:54

Upfront Use of Next-Generation ALK Inhibitors in NSCLC

Next-Generation ALK Inhibitors 0:05:53

Next-Generation ALK Inhibitors in Non-Small Cell Lung Cancer

First and Second 0:22:10

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

Treating NSCLC Patients 0:04:37

Treating NSCLC Patients With a Next-Generation ALK TKI

Next-Generation ALK Inhibitors, 0:04:23

Next-Generation ALK Inhibitors, Activity for Brain Lesions

2023 Best of 0:30:32

2023 Best of Lung: Targeted Therapies in Lung Cancer

ALK mutations in 0:05:09

ALK mutations in ctDNA predict responses to next generation ALK TKIs in NSCLC

ALK Inhibitor Sequencing 0:06:27

ALK Inhibitor Sequencing in NSCLC

Choosing the best 0:01:24

Choosing the best ALK inhibitor for lung cancer

Development of ALK 0:04:37

Development of ALK Inhibitors in Advanced Non-Small Cell Lung Cancer

New ALK Inhibitor 0:02:15

New ALK Inhibitor Drugs vs Xalkori (Crizotinib) for ALK+ Lung Cancer Patients

ALK Positive Lung 0:42:31

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

Next-Generation Targeted Therapies 0:07:44

Next-Generation Targeted Therapies in Non-Small Cell Lung Cancer

How Do the 0:04:58

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

Third-Generation ALK Inhibitors 0:08:17

Third-Generation ALK Inhibitors for NSCLC

ALK and ROS1 0:40:53

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

Second-Line Treatment for 0:08:24

Second-Line Treatment for ALK-Positive NSCLC

Second-Generation ALK Inhibitors 0:07:11

Second-Generation ALK Inhibitors in Non-Small Cell Lung Cancer